when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

NOVARTIS · news · pharmadog

← back to NOVARTIS

News mentioning NOVARTIS

367 stories

Aug 4, 26J&J pharma leader to retire; Krystal slumps on gene therapy missbiopharma dive

Aug 4, 26Icon inks Anthropic partnership to deploy Claude into clinical trialsfiercebiotech

Aug 4, 26Vertex unfazed by competitive IgAN space as FDA verdict loomsbiospace

Aug 3, 26FDA expands Pluvicto label, making it available to most metastatic prostate cancer patientsendpoints

Aug 3, 26Curium strikes up to $8B deal for radiopharma rival Lantheusfiercebiotech

Aug 3, 26Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad ideafiercebiotech

Aug 3, 26Recon: AstraZeneca, BMS discuss merger; FDA broadens indication for Novartis’ Pluvictoraps

Jul 31, 26Trump administration tries again to institute rebates in 340Bbiopharma dive

Jul 31, 26Moderna maintains 10% growth target despite Phase 3 norovirus missbiospace

Jul 30, 26GSK pens $110M biological datasets pact with AI biotech Relationfiercebiotech

Jul 30, 26Biogen validated the Alzheimer’s tau theory. CEO Viehbacher still isn’t betting the storebiospace

Jul 29, 26Processa acquires Vidya for potential BTK inhibitor rival to Novartis’ Rhapsidofiercebiotech

Jul 28, 26GSK shares rise as $2.5B cost-cutting plan unveiledbiospace

Jul 28, 26Eli Lilly tops new biopharma ranking on launch success, development speedfiercebiotech

Jul 28, 26GSK unveils 3-year cost-saving plan to fund late-stage R&D, move research HQ to AZ's backyardfiercebiotech

Jul 27, 26Lilly, AbbVie climb aboard in vivo CAR T train—but safety remains a hurdlebiospace

Jul 25, 26Anthropic’s life science plans; Novartis CEO on China deals; and moreendpoints

Jul 24, 26Scribe records upsized $129M IPO to bankroll lipid-lowering genetic medsfiercebiotech

Jul 22, 26Webinar: From Clinical to Commercial: Talent Strategies for Biopharma Growthbiospace

Jul 22, 26Novartis scraps mid-stage radiopharma asset as Pluvicto soarsbiospace

Jul 22, 26Q2 earnings underway, FDA’s CRL kerfuffle, IPOs full speed ahead in H2biospace

Jul 22, 26AI data becomes sticking point in biopharma dealmakingbiospace

Jul 21, 26Agios scraps sickle cell drugbiopharma dive

Jul 21, 26Novartis CEO says latest China deals are just following the scienceendpoints

Jul 21, 26Novartis climbs on upbeat drug sales as key readouts loombiopharma dive

Jul 21, 26STAT+: Anthropic deepens work with rare disease drugsstat

Jul 21, 26Novartis stays 'geography-agnostic' in dealmaking amid flurry of China dealsbiospace

Jul 21, 26‘We’ve been looking for a novel approach’: Why Novartis CEO ended ADC holdout for $1.5B Myricx dealfiercebiotech

Jul 21, 26Novartis drops phase 2 radioligand therapy, but CEO’s commitment to modality ‘unchanged’fiercebiotech

Jul 20, 26Bristol Myers to build ‘powerful’ AI factory; Samsung Biologics bids for peptide makerbiopharma dive

← prevpage 10 of 13next →